The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Progression From Newly Acquired Impaired Fasting Glusose to Type 2 Diabetes
Open accessAbstract
OBJECTIVE—We sought to estimate the rate of progression from newly acquired (incident) impaired fasting glucose (IFG) to diabetes under the old and new IFG criteria and to identify predictors of progression to diabetes. RESEARCH DESIGN AND METHODS—We identified 5,452 members of an HMO with no prior history of diabetes, with at least two elevated fasting glucose tests (100–125 mg/dl) measured between 1 January 1994 and 31 December 2003, and with a normal fasting glucose test before the two elevated tests. All data were obtained from electronic records of routine clinical care. Subjects were followed until they developed diabetes, died, left the health plan, or until 31 December 2005. RESULTS—Overall, 8.1% of subjects whose initial abnormal fasting glucose was 100–109 mg/dl (added IFG subjects) and 24.3% of subjects whose initial abnormal fasting glucose was 110–125 mg/dl (original IFG subjects) developed diabetes (P < 0.0001). Added IFG subjects who progressed to diabetes did so within a mean of 41.4 months, a rate of 1.34% per year. Original IFG subjects converted at a rate of 5.56% per year after an average of 29.0 months. A steeper rate of increasing fasting glucose; higher BMI, blood pressure, and triglycerides; and lower HDL cholesterol predicted diabetes development. CONCLUSIONS—To our knowledge, these are the first estimates of diabetes incidence from a clinical care setting when the date of IFG onset is approximately known under the new criterion for IFG. The older criterion was more predictive of diabetes development. Many newly identified IFG patients progress to diabetes in <3 years, which is the currently recommended screening interval.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Standards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,885
Categorical Data Analysis Using the SAS System
(1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 1,869
Writing committee, Unwin, N., Shaw, J., Zimmet, P., & Alberti, K. G. M. M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00835.x · Cited by 1,108
Laaksonen, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf145 · Cited by 916
The Metabolic Syndrome as Predictor of Type 2 Diabetes
Lorenzo, C., Okoloise, M., Williams, K., Stern, M. P., & Haffner, S. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3153 · Cited by 803
Components of the “Metabolic Syndrome” and Incidence of Type 2 Diabetes
Hanson, R. L., Imperatore, G., Bennett, P. H., & Knowler, W. C. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3120 · Cited by 590
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1108 · Cited by 568
Meigs, J. B., Muller, D. C., Nathan, D. M., Blake, D. R., & Andres, R. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1475 · Cited by 338
Shaw, J. E., Zimmet, P. Z., de Courten, M., Dowse, G. K., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Alberti, K. G. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.399 · Cited by 329
Hanley, A. J. G., Karter, A. J., Williams, K., Festa, A., D’Agostino, R. B., Wagenknecht, L. E., & Haffner, S. M. (2005) · Circulation · doi:10.1161/circulationaha.105.559633 · Cited by 266
Borch‐Johnsen, K., Colagiuri, S., Balkau, B., Gl�mer, C., Carstensen, B., Ramachandran, A., Dong, Y., & Gao, W. (2004) · Diabetologia · doi:10.1007/s00125-004-1468-6 · Cited by 154
Mode of onset of type 2 diabetes from normal or impaired glucose tolerance
Ferrannini, E., Nannipieri, M., Williams, K., Gonzales, C., Haffner, S. M., & Stern, M. P. (2004) · Diabetes · doi:10.2337/diabetes.53.1.160 · Cited by 153
Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.
Vaccaro, O., Ruffa, G., Imperatore, G., Iovino, V., Rivellese, A. A., & Riccardi, G. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1490 · Cited by 118
Effects of Changing Diagnostic Criteria on the Risk of Developing Diabetes
Dinneen, S. F., Maldonado, D., Leibson, C. L., Klee, G. G., Li, H., Melton, L. J., & Rizza, R. A. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1408 · Cited by 117
Reproducibility of the Diagnosis of Diabetes Over a 30-Month Follow-Up
Eschwège, É., Charles, M.-A. A., Simon, D., Thibult, N., & Balkau, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1941 · Cited by 68
Gimeno, S. G. A., Ferreira, S. R. G., Franco, L. J., & Iunes, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1889 · Cited by 60
Higher Medical Care Costs Accompany Impaired Fasting Glucose
Nichols, G. A., & Brown, J. B. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2223 · Cited by 49
Self-citationDetection of Undiagnosed Diabetes and Other Hyperglycemia States
Schmidt, M. I., Duncan, B. B., Vigo, Á., Pankow, J. S., Ballantyne, C. M., Couper, D. J., Brancati, F. L., Folsom, A. R., & for the ARIC Investigators (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1338 · Cited by 37
de Vegt, F., Dekker, J. M., Jager, A., Hienkens, E., Kostense, P. J., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (2001) · JAMA · doi:10.1001/jama.285.16.2109 · Cited by 10
Cited by
Metabolic Syndrome and Incident Diabetes
Ford, E. S., Li, C., & Sattar, N. (2008) · Diabetes Care · doi:10.2337/dc08-0423 · Cited by 577
Defining and Characterizing the Progression of Type 2 Diabetes
Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s301 · Cited by 573
Glycemic control and complications in type 2 diabetes mellitus
Stolar, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.004 · Cited by 356
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
Waters, D. D., Ho, J. E., DeMicco, D. A., Breazna, A., Arsenault, B. J., Wun, C.-C., Kastelein, J. J., Colhoun, H., & Barter, P. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.047 · Cited by 333
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
Metadata
- Authors
- Nichols, G. A., Hillier, T. A., & Brown, J. B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-02-01
- Volume
- 30
- Issue
- 2
- Pages
- 228-233
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2153509994
- Cited by
- 272
- References
- 24
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.